Sanofi

Sanofi: Q3/2012 Business EPS reflects patent expirations

Uutinen   •   Loka 25, 2012 23:10 EEST

Net sales lost to generic competition were € 448 million in the quarter, primarily due to generic competition to Eloxatin in the U.S.